Department of General Surgery, Section of Gastroenterological Surgery, Ankara Etlik City Hospital, Ankara, Turkey.
Department of Radiology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey.
Langenbecks Arch Surg. 2023 Sep 13;408(1):356. doi: 10.1007/s00423-023-03101-1.
PURPOSE: In the last decades, total mesorectal excision (TME) and neoadjuvant chemoradiotherapy (nCRT) have produced an undeniable improvement in the treatment of rectal cancer. However, local recurrence is still an important problem, and the effect of lateral lymph node (LLN) involvement on local recurrence is a controversial issue. The aim of this study was to investigate the effects of LLN status on local recurrence and survival in rectal cancers treated with nCRT + TME. METHODS: Clinical features, pre- and post-nCRT lateral pelvic region imaging, long-term local recurrence, and the survival outcomes of 114 patients who underwent nCRT + TME for rectal cancer were evaluated. RESULTS: On MRI before nCRT, 20 (17.5%) patients had lateral lymph nodes (LLN+), and 94 (82.5%) patients had no lymph nodes in the lateral pelvic compartments (LLN-). Local recurrences at 1 year in LLN+ and LLN- patients were 3 (15.8%) and 2 (2.3%), respectively (p=0.039). Five-year local recurrence-free survival rates and the mean duration of recurrence-free survival in LLN+ and LLN- patients were 56.2%, 42.6 months, and 87.3% 66.9 months, respectively (p=0.001). Disease-free survival and overall survival were shorter in LLN+ patients, but the difference was not statistically significant (p=0.096 and p=0.46, respectively). In the multivariate analysis, LLN involvement was determined to be an independent risk factor for local recurrence-free survival (Hazard Ratio 4.54, p=0.003). CONCLUSION: Lateral lymph node involvement causes local recurrence to remain high after nCRT + TME. LLN status should be considered in treatment planning. Further studies are needed to define precise criteria for LLN involvement and the effect of LLND on local recurrence and survival.
目的:在过去的几十年中,全直肠系膜切除术(TME)和新辅助放化疗(nCRT)在直肠癌的治疗中取得了不可否认的改善。然而,局部复发仍然是一个重要的问题,侧方淋巴结(LLN)受累对局部复发的影响是一个有争议的问题。本研究旨在探讨 nCRT+TME 治疗直肠癌时 LLN 状态对局部复发和生存的影响。
方法:评估了 114 例接受 nCRT+TME 治疗的直肠癌患者的临床特征、nCRT 前后侧盆腔区域影像学、长期局部复发和生存结果。
结果:在 nCRT 前的 MRI 上,20 例(17.5%)患者有侧方淋巴结(LLN+),94 例(82.5%)患者无侧盆腔淋巴结(LLN-)。LLN+和 LLN-患者的 1 年局部复发率分别为 3 例(15.8%)和 2 例(2.3%)(p=0.039)。LLN+和 LLN-患者的 5 年局部无复发生存率和无复发生存期的平均值分别为 56.2%、42.6 个月和 87.3%、66.9 个月(p=0.001)。LLN+患者的无病生存率和总生存率较短,但差异无统计学意义(p=0.096 和 p=0.46)。在多变量分析中,LLN 受累被确定为局部无复发生存的独立危险因素(风险比 4.54,p=0.003)。
结论:nCRT+TME 后,侧方淋巴结受累导致局部复发率仍然较高。在治疗计划中应考虑 LLN 状态。需要进一步研究以确定 LLN 受累的精确标准以及 LLND 对局部复发和生存的影响。
World J Gastroenterol. 2020-6-7
Abdom Radiol (NY). 2025-8-9
World J Gastrointest Surg. 2024-4-27
Int J Colorectal Dis. 2021-11